AUTL - Autolus Therapeutics plc

1.48
0.060   4.054%

Share volume: 1,538,589
Last Updated: 04-28-2026
Pharmaceutical Products/Biological Products, Except Diagnostic Substances: 0.20%

PREVIOUS CLOSE
CHG
CHG%
$1.42
0.06
0.04%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
37%
Profitability 35%
Dept financing 33%
Liquidity 75%
Performance 30%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
2.78%
1 Month
16.54%
3 Months
3.50%
6 Months
1.37%
1 Year
12.98%
2 Year
-61.05%
Key data
Stock price
$1.48
P/E Ratio 
N/A
DAY RANGE
$1.40 - $1.50
EPS 
-$1.08
52 WEEK RANGE
$1.15 - $2.70
52 WEEK CHANGE
$4.96
MARKET CAP 
0.000
YIELD 
N/A
SHARES OUTSTANDING 
266.143 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-13-2025
BETA 
2.14
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$1,109,132
AVERAGE 30 VOLUME 
$1,460,620
Company detail
CEO: Christian M. Itin
Region: US
Website: autolus.com
Employees: 330
IPO year: 2018
Issue type: American Depository Receipt (ADR’s)
Market: XNAS
Industry: Pharmaceutical Products/Biological Products, Except Diagnostic Substances
Sector: Manufacturing

Autolus Therapeutics plc develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trials for adult ALL. It also focuses on developing AUTO5, a hematological product candidate, which is in preclinical development.

Recent news